Bio-Engineered Cardiovascular and Skin Repair and Replacement Products to Lead Growth in the U.S. and Worldwide Tissue Engineering Markets, According to Medtech Insight Analysis

August 9, 2004

Newport Beach CA-- (BUSINESS WIRE) -- With its beginnings in tissue-engineered skin for burn and accident victims and diabetic foot ulcers, the market for tissue-engineered therapeutic products is evolving rapidly. It now includes advanced, futuristic applications such as bone marrow and cartilage regeneration and artificial organs, all coming about because of significant advances in biocompatible materials, biological growth factors, cell culture techniques, genetic engineering, immunoisolation techniques, and immunosuppressive drugs. These developments all amount to a major market opportunity: the total worldwide potential market for tissue-engineered products, totaling almost $125 billion in 2003, is forecast to reach over $196 billion in 2013.

These market developments are the focus of Medtech Insight's comprehensive new 372-page report, "Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets." This analysis examines the U.S. and worldwide potential markets in 2003 forecast to 2013 for existing and emerging synthetic and biologically derived products used in organ regeneration, cardiovascular, musculoskeletal, neurological, urological, and skin repair and replacement applications.

Included are analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. and worldwide markets for: tissue-engineered cardiovascular products including angiogenesis, bypass grafting, congenital heart defect repair, heart valve repair and replacement, myocardial tissue regeneration, and restenosis prevention products; tissue-engineered musculoskeletal products including fracture fixation and orthopedic/spinal repair, cartilage and joint, ligament, and meniscal repair and replacement, and viscosupplementation products; tissue-engineered neurological products including potential treatments for a number of neurological diseases, spinal cord injury, and stroke; tissue-engineered urological products including bladder repair and slings, penile prostheses, ureter regeneration and repair, and urethra repair; tissue-engineered skin repair and replacement products including breast reconstruction, wound repair, and ulcer treatment; and tissue-engineered organ regeneration and replacement products, including bone marrow, liver, pancreas, renal tubule, and small intestine products. Profiles for 25 key competitors in this market are also included, and 73 detailed exhibits.

Companies detailed in this report include Aastrom Biosciences, Boston Scientific, CellECT Bio, Cook, CryoLife, Curis, Cytomatrix/CordLife, GenVec, Genzyme, Integra LifeSciences, IsoTis OrthoBiologics, LifeCell, Osiris Therapeutics, Osteotech, Protein Polymer Technologies, ReGen Biologics, Regeneration Technologies, Smith & Nephew, StemCells, TEI Biosciences, Tepha, Titan Pharmaceuticals, Teraklin, Valentis, and Wright Medical Technology, among many others. A full table of contents for this report and ordering information can be viewed at http://www.medtechinsight.com/ReportA401.html.

Recently acquired by Windhover Information Inc. (www.windhover.com), publisher of IN VIVO: The Business & Medicine Report and Start-UP: Windhover's Review of Emerging Technologies, Medtech Insight is a leading provider of business information for the medical technology marketplace. The company publishes the monthly "medtech insight" newsletter and a wide selection of comprehensive Market & Technology Reports, holds several emerging medical technology investment conferences annually, and provides custom consulting and market research services.

Copyright © 2004 Business Wire.

This article posted August 27, 2004.